Antimicrobial Susceptibility of Stenotrophomonas maltophilia Isolates from a Korean Tertiary Care Hospital

Yonsei Medical Journal

Volumn 53, Issue 2, 2012, Pages 439-441

  Chung, Hae Sun ^a   Hong, Seong Geun ^b   Lee, Yangsoon ^a   Kim, Myungsook ^a   Yong, Dongeun ^a   Jeong, Seok Hoon ^a   Lee, Kyungwon ^a   Chong, Yunsop ^a  

^a Yonsei University College of Medicine   (South Korea)

^b CHA University   (South Korea)

Author keywords

Antimicrobial susceptibility; Levofoxacin; Minocycline; Stenotrophomonas maltophilia; Trime thoprim sulfamethoxazole

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFEPIME; CEFTAZIDIME; CHLORAMPHENICOL; CLAVULANATE POTASSIUM PLUS TICARCILLIN; CLAVULANIC ACID; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MINOCYCLINE; MOXIFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TAZOBACTAM; TETRACYCLINE; TICARCILLIN; TIGECYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SOUTH KOREA; STENOTROPHOMONAS MALTOPHILIA;

ANTI-INFECTIVE AGENTS; HOSPITALS; KOREA; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; OFLOXACIN; STENOTROPHOMONAS MALTOPHILIA; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84863119964     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2012.53.2.439     Document Type: Article

References (17)

1. Looney WJ, Narita M, Mühlemann K. Stenotrophomonas malto-philia: an emerging opportunist human pathogen. Lancet Infect Dis 2009;9:312-23.
2. Sader HS, Jones RN. Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. Int J Antimicrob Agents 2005;25:95-109.
3. Jones RN, Sader HS, Beach ML. Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001). Int J Antimicrob Agents 2003;22:551-6.
4. Nicodemo AC, Paez JI. Antimicrobial therapy for Stenotroph-omonas maltophilia infections. Eur J Clin Microbiol Infect Dis 2007;26:229-37.
5. Wang WS, Liu CP, Lee CM, Huang FY. Stenotrophomonas malto-philia bacteremia in adults: four years' experience in a medical center in northern Taiwan. J Microbiol Immunol Infect 2004;37: 359-65.
6. BSAC Methods for antimicrobial susceptibility testing. Available at http://www.bsac.org.uk/Susceptibility+Testing/GUIDELINES+Standardized+Disc+Susceptibility+Testing+Method. [access on June 2011]
7. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement, M100-S21. Wanye, PA: Clinical and Laboratory Standards Institute; 2011.
8. Song JH, Sung JY, Kwon KC, Park JW, Cho HH, Shin SY, et al. Analysis of acquired resistance genes in Stenotrophomonas malto-philia. Korean J Lab Med 2010;30:295-300.
9. Seol SY, Jang KS, Jeong OG, Cho ER, Kim NH, Yu HS, et al. Antimicrobial resistance and molecular epidemiologic characteristics of Stenotrophomonas maltophilia isolated from clinical specimens. J Korean Soc Microbiol 2000;35:239-50.
10. Livermore DM, Hope R, Brick G, Lillie M, Reynolds R; BSAC Working Parties on Resistance Surveillance. Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gram-negative bacteria from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother 2008;62 Suppl 2:255-63.
11. Farrell DJ, Sader HS, Jones RN. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob Agents Chemother 2010;54:2735-7.
12. Cantón R, Valdezate S, Vindel A, Sánchez Del Saz B, Maíz L, Baquero F. Antimicrobial susceptibility profile of molecular typed cystic fibrosis Stenotrophomonas maltophilia isolates and differences with non cystic fibrosis isolates. Pediatr Pulmonol 2003;35: 99-107.
13. Gülmez D, Hascelik G. Stenotrophomonas maltophilia: antimicrobial resistance and molecular typing of an emerging pathogen in a Turkish university hospital. Clin Microbiol Infect 2005;11: 880-6.
14. Valenza G, Tappe D, Turnwald D, Frosch M, König C, Hebestreit H, et al. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J Cyst Fibros 2008;7:123-7.
15. Galles AC, Jones RN, Sader HS. Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas malto-philia isolates: can moxifoxacin activity be predicted by levofox-acin MIC results? J Chemother 2008;20:38-42.
16. Valdezate S, Vindel A, Loza E, Baquero F, Cantón R. Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia clinical strains. Antimicrob Agents Chemother 2001;45:1581-4.
17. Vartivarian S, Anaissie E, Bodey G, Sprigg H, Rolston K. A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy. Antimicrob Agents Chemother 1994;38:624-7.